Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer’s Hympavzi secures FDA expanded indications for haemophilia
Phase III BASIS trial supported Hympavzi approval, showing a 93% reduction in bleeding rate versus on-demand intravenous agents. Credit: Sai Thaw Kyar / Shutterstock.com.
Phase III BASIS trial supported Hympavzi approval, showing a 93% reduction in bleeding rate versus on-demand intravenous agents. Credit: Sai Thaw Kyar / Shutterstock.com.